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When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition
and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53
pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia.
The p53 protein is a transcription factor, which is rapidly stabilised by cellular stresses and which has a major role in the cell
responses to these stresses. The aim of this review is to compile what has been reported until now about the interconnection
between these two important pathways. Indeed, according to the cell line, the severity and the duration of hypoxia, oxygen
deﬁciency inﬂuences very differently p53 protein level and activity. Conversely, p53 is also described to affect HIF-1a stability,
one of the two subunits of HIF-1, and HIF-1 activity. The direct and indirect interactions between HIF-1a and p53 are describedas
well as the involvement in this complex network of their respective ubiquitin ligases von Hippel Lindau protein and murine
double minute 2. Finally, the synergistic or antagonistic effects of p53 and HIF-1 on some important cellular pathways are
discussed.
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In case of a decrease in oxygen availability for the cells, the
hypoxic pathway is induced with the activation of the HIF-1
(hypoxia-inducible factor 1) transcription factor. HIF-1 is
constituted of two subunits called HIF-1a and HIF-1b (or
ARNT for aryl hydrocarbon receptor nuclear translocator).
Although HIF-1b is constitutively expressed, HIF-1a is
precisely regulated by hypoxia.
1 On the other hand, p53
pathway is activated by various stresses. The p53 protein is
codedbytheTP53gene,whichisthemostfrequentlymutated
gene in human tumours.
2 The p53 pathway is indeed
inactivated in most tumours because it functions as the
‘guardian of the genome’.
2 p53 acts as a tetrameric transcrip-
tion factor that induces the transcription of hundreds of target
genes, which are involved in regulating apoptosis, cell cycle
and DNA repair among others.
3 Furthermore, p53 has DNA-
binding-independent functions. It indeed interacts with pro-
teins of the Bcl-2 family and translocates to the mitochondria
to induce cell death.
4 In basal conditions, p53 is kept at very
low levels by MDM2 (murine double minute 2)-mediated
ubiquitination and subsequent proteasomal degradation,
5,6
while it is stabilised by various cellular stresses. HIF-1 and
p53 pathways have been broadly investigated since they are
both involved in the emergence and progression of various
diseases, cancer being one of the most important. In this
review, we discuss how hypoxia modulates the p53 pathway,
the inﬂuence of p53 on the hypoxic pathway, the direct and
indirect interactions that have been described between the
HIF-1 and p53 transcription factors to ﬁnally conclude on how
these factors modulate various cellular pathways.
Effects of Hypoxia on p53 Protein Level and Activity
Hypoxia has frequently been described to be a p53 inducer.
7
However, in some cases, hypoxia, alone or in combination
with other stresses, has no effect or even decreases p53
protein level.
8
Hypoxia increases p53 protein level. Already in 1994,
Graeber et al.
9 showed that cells exposed to hypoxia
accumulate p53 protein. This accumulation increased with
the duration of the hypoxia incubation as well as with the
decrease in the pO2 level.
10 Most studies showed that the
increase in p53 protein level during hypoxia is due to a stabili-
sation that is dependent on the presence of HIF-1a.
11,12
However, HIF-1a upregulation is not sufﬁcient for p53
induction.
13,14 Hammond et al.
15 indeed showed that HIF-1a
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and 2% oxygen, whereas p53 protein accumulated in
response to 0.02% oxygen only. Many different hypotheses
have been elaborated to explain the increase in p53 protein
level during hypoxia but a complete comprehension has not
been reached yet (Figure 1).
Many investigators highlight a putative important role of
MDM2 in this process. Chen et al.
16 proposed that HIF-1a
suppresses MDM2-mediated p53 ubiquitination and blocks
MDM2-mediated nuclear export of p53. A hypoxia-induced
decrease in MDM2 level has indeed been observed in several
studies.
17–19 However, the way by which hypoxia is modulat-
ing MDM2 abundance and/or activity may vary, involving p38
MAPK
19 or PNUTS (protein phosphatase-1 nuclear targeting
subunit)
20 activation.
MDM2-independentpathwayshavealsobeensuggestedto
explainincreasedp53stabilityunderhypoxia.Stabilisationvia
serine 15 phosphorylation is frequently observed under
hypoxia and could be the result of the activation of ATM
(ataxia-telangiectasia mutated) or ataxia-telangiectasia mu-
tated and Rad3-related kinases by hypoxia.
15,21 The hypoxia-
induced PNUTS could also increase p53 activity via the
inhibition of protein phosphatase-1, a phosphatase for p53.
20
Mitochondrial generation of reactive oxygen species (ROS)
could also contribute to p53 induction.
22 Finally, the hypoxia-
induced decrease in carboxyl terminus of HSP70-interacting
protein transcription, a protein involved in the induction of p53
proteasomal degradation, has been shown to be responsible
forp53accumulation inthe heartafter myocardial infarction.
23
Although most of these reports suggested p53 protein
stabilisation under hypoxia, two reports explained increased
p53 protein level by either increased p53 mRNA translation
without any change in mRNA level
24 or by an increase in p53
mRNA level.
25 Galban et al.
24 indeed showed that pVHL
(VonHippelLindauprotein),whichisatranscriptionaltargetof
HIF-1 and therefore induced under hypoxia, could enhance
p53 translation in a way involving the RNA-binding protein
HuR.
In conclusion, hypoxia was frequently shown to increase
p53 protein level, with HIF-1a and MDM2 being probably
involved in most cases. However, a lot of different hypotheses
have been pointed out, most of them only by one group, to
explain the p53 increase under hypoxia. It would therefore be
interesting to investigate whether these different results could
be reproduced in different settings and whether several of
these complementary pathways could be activated simulta-
neously in one setting.
Downstream effects of the hypoxia-induced increase in
p53 protein level. An increase in p53 protein level usually
induces cell cycle arrest or apoptosis. p53-dependent cell
cycle arrest of hypoxic cells has indeed been described.
26
However, several reports observed that hypoxia-induced cell
cycle arrest occurred independently of p53.
9,27 In most
cases, the increase in p53 level in cells exposed to hypoxia
induces apoptosis,
7 although an increase in p53 protein level
without subsequent apoptosis has also been observed.
28
The presence of both HIF-1a and p53 seems to be essential
for the hypoxia-induced cell death.
The induction of p53-dependent apoptosis by hypoxia or by
DNA damage are both described to involve the mitochondrial
outer membrane permeabilisation, cytochrome c release and
the subsequent activation of caspase-9 and caspase-3.
However, these stresses do not activate p53 through the
same pathway.
29,30 Although DNA damage induces an
increase in p53-target gene expression, hypoxia is mainly
Figure 1 Schematicrepresentationof thedifferentpathwaysthathave beenproposedto explain thehypoxia-induced increase in p53mRNAabundance,translation, p53
proteinstabilityandactivityaswellasthehypoxia-induceddecreaseinp53proteasomaldegradation.ATM,ataxia-telangiectasiamutated;ATR,ataxia-telangiectasiamutated
andRad3-related;CHIP, carboxylterminusof HSP70-interactingprotein; HIF-1a, hypoxia-inducible factor-1a;MDM2,murine double minute2; PNUTS, proteinphosphatase-
1 nuclear targeting subunit; PP1, protein phosphatase-1; pVHL, von Hippel Lindau protein; ROS, reactive oxygen species; Ub, ubiquitin
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repression, that is, via a decrease in gene expression.
18,31
In 1998, An et al.
11 showed that HIF-1a overexpression
under normoxia increased p53 activity. However, the
responses of cells within physiological levels of HIF-1a during
real hypoxia could be different. Indeed, in most cases, the
hypoxia-induced p53 is not coupled with the induction of the
most common p53 target genes.
31–33 The ﬁrst explanation
that is given to explain the weak transactivation activity of
hypoxia-induced p53 is that p53 is not bound to the promoter
of BAX or PUMA during hypoxia.
32 However, it was observed
that p53 is actually bound to the promoter of most p53 target
genes but that the transactivation is not induced
29 because
CBP (CREB-binding protein) and p300 co-activators are not
recruited.
31 Two main hypotheses have been given to explain
the absence of co-activator recruitment. The ﬁrst one is that it
could be due to a competition between p53 and HIF-1 for the
interaction with these co-activators.
34 p300 is indeed required
for the transactivation activity of HIF-1 as well as of p53 and
both proteins are interacting with the same domain (CH1) of
p300.
35 This competition has been shown to be regulated by
cockayne syndrome B (CSB) protein, which is a HIF-1 target
gene.
36 In CSB mutant cells exposed to hypoxia-mimicking
agents, the p53 pathway is indeed massively activated, as is
the recruitment of RNA polymerase II at the promoter of p53
target genes. On the contrary, for the HIF-1 target genes,
despite correct HIF-1 recruitment on their promoter, down-
stream events such as RNA polymerase II, TFIIB and p300
recruitment do not actually occur.
36 These investigators
demonstrate that CSB and p300 interact with p53, these
interactions being mutually exclusive. This led them to
postulate that a HIF-1-dependent increase in CSB level would
decrease the level of p53-bound p300 and consequently
increase the level of p300 available for HIF-1.
36 The second
reason that is evoked for the absence of co-activators
recruitment by hypoxia-induced p53 is that the posttransla-
tional modiﬁcations of p53 occurring during hypoxia are not
the ones needed for the binding of co-activators or are mainly
leading to the recruitment of transrepressors.
31 For example,
it was observed that acetylation of p53 on K320 amino acid,
probably by p300/CBP-associated factor, is reduced under
hypoxia-mimicking conditions while the acetylation of this
residue is known to be important for the induction of some p53
target genes.
37 Hypoxia-induced p53 is also described to
interact with the transcriptional corepressor mSin3A instead
of the transcriptional co-activator p300 whereas p53 induced
by DNA damage interacts with both proteins.
18
The major activity of hypoxia-induced p53 is therefore
reported to be transrepression, this transrepression
activity being essential for the p53-induced apoptosis under
hypoxia.
31 The p53-repressed genes that are really involved
in triggering apoptosis are not deﬁned yet but HIAP/BIRC3,
a protein interfering with caspase activation, could be one of
them.
33 The preferential activation of transrepression com-
pared with transactivation makes sense in the context of
hypoxia because the cell tends to reduce its energetic
expenditure when the limited oxygen concentration reduces
ATP production.
Nevertheless,p53isdescribedtoinducethetranscriptionof
a small subset of its target genes including BNIP3L
32 and
FAS/CD95.
33 As the promoter of these two genes also
contains a hypoxia response element, their transactivation
could necessitate the cooperative binding of both HIF-1 and
p53 in order to be properly induced under hypoxia.
32,33 The
presence of HIF-1-binding sites in the proximity of the p53-
binding sites could contribute to elevate the local level of
CBP.
32 However, in some conditions, p53-transactivating
activity has been observed with induction of PUMA or BAX
mRNA during hypoxia.
25,26,38 The induction of p21 by hypoxia
is also used in some reports to suggest a p53-transactivating
activity
9,39 but it is important to note that p21 has also been
described to be induced by hypoxia in a p53-independent
manner.
40
Hypoxia-induced p53 could also have DNA-binding-
independent activity. Sansome et al.
41 reported that hypoxia
induces p53 translocation toward mitochondria. In a rat
model, it was also observed that transient global cerebral
ischaemia-induced mitochondrial translocation of p53 as well
as its binding to the anti-apoptotic protein BCL-XL, inducing
the release of cytochrome c from the mitochondria and
subsequent cell death.
42 However, others observed p53 only
in the nuclear compartment.
31
Altogether, these data indicate that hypoxia-induced p53
is able to induce apoptosis but in a different way that when
it is activated by DNA damage. Indeed, under hypoxia, p53
transactivation activity is weak probably due to the lack of
co-activator recruitment. Some p53 target genes are never-
theless transcribed, mainly if p53 works in cooperation with
other hypoxia-induced transcription factors. However, its
transrepression and DNA-binding-independent activities are
sufﬁcient to provoke cell death.
Finally,ithastobenotedthattheroleofHIF-2ainregulating
the p53 pathway has only been recently investigated. In 2009,
Bertout et al.
43 showed that HIF-2a deﬁciency promotes p53
Ser15 phosphorylation and p53-mediated responses by
disrupting cellular redox homeostasis. Similarly, Roberts
et al.
44 showed that accumulation of HIF-2a, in VHL
 /  and
HIF-1a
 /  clear cell renal cell carcinoma, led to Akt-mediated
activation of MDM2 and subsequent suppression of p53.
According to these two reports, HIF-2a would have a negative
effect on p53 suggesting an opposite role as compared with
what is described for HIF-1a.
Hypoxia has no effect on p53 protein level or decreases
it. Although frequently described, the induction of p53 by
hypoxia is not occurring in all cases. It seems to be depen-
ding on various factors such as the severity of hypoxia, its
duration as well as according to the cell line. Halterman and
Federoff
45 suggested that under mild conditions, hypoxia
induces HIF-1-dependent transcriptional activation of adap-
tive genes whereas under conditions of sustained hypoxia,
HIF-1a stabilisation increases cellular p53 level and
promotes cell death. It was indeed shown that in RKO
cells, p53 is stabilised at 0.02% of oxygen but not at 2% after
24h incubation although HIF-1a is stabilised at 2%.
15 At 0%
oxygen, Schmid et al.
34 observed an increase in p53 protein
level after 16h incubation but not before. Moreover, Cosse
et al.
46 showed that if hypoxia (1% oxygen during 16h)
induced an increase in p53 protein level in MCF-7 cells, it
was not the case in A549 cells and the p53 level was even
Reciprocal inﬂuence of p53 and hypoxia
A Sermeus and C Michiels
3
Cell Death and Diseasereduced by hypoxia in HepG2 cells. Chen et al.
47 showed
that hypoxia increased p53 protein level in cytotrophoblasts
while it reduced it in syncytiotrophoblasts. Other reports
stress the fact that hypoxia alone is not sufﬁcient to induce
p53 but that DNA damage, acidosis (a secondary effect of
the Pasteur effect caused by hypoxia) or reoxygenation are
needed to observe this effect.
14,48,49 Situations in which
hypoxia does not affect p53 protein level have therefore been
frequently described, hypoxia inducing or not apoptosis.
50,51
Wouters et al.
52 have even not observed any effect of
hypoxia (o0.1% oxygen) on p53 protein level for up to 48h.
Furthermore, Amellem et al.
53 showed that severe hypoxia
induced apoptosis in a p53-dependent manner but without
any change in p53 protein level.
In some situations, as already evoked, hypoxia can even
induce a decrease in p53 protein level.
14,47,54–57 As for the
reasons explaining how hypoxia increased p53 level, several
hypotheses have been made to understand it (Figure 2). It is
interesting to see that some hypotheses are just the opposite
that the ones described here above, suggesting that hypoxia
could have totally opposite effects according to the cell type,
the severity and the duration of hypoxia. Most groups
suggested that decreased p53 level under hypoxia was due
to p53 protein degradation. It could occur after p53 ubiquitina-
tion by MDM2, which has been described to be induced by
hypoxia.
58,59 Zhang and Hill
58 proposed that hypoxia induces
MDM2 upregulation at the mRNA level in a p53-independent
manner. An increase in MDMX expression has also been
observed in hypoxic cells together with a reduced phosphor-
ylation of p53 at Ser392.
47 The involvement of hypoxia-
induced increase in casein kinase 2 level and activity
60 or p53
cleavage by calpains
56 has also been proposed to contribute
to the decrease in p53 protein level observed during hypoxia.
Furthermore, hypoxia could as well decrease p53 protein
stability by other means. The phosphorylation of p53 at Ser15
is inhibited by hypoxia-induced nucleophosmin.
61 Rohwer
et al.
62 also showed that HIF-1a knock-down strongly
increased the amount of p53 protein in the presence of
5-ﬂuorouracil, suggesting that HIF-1a reduced the formation
of ROS leading to decreased p53 stabilisation. Finally,
hypoxia is known to induce HIPK2 (homeodomain-interacting
protein kinase 2) disappearance, resulting in increased p53
‘mutant-like’ conformation and inhibition of apoptosis.
63 This
decreaseinHIPK2levelcoulddependonthehypoxia-induced
MDM2, on the RING family ligase seven in absentia homo-
log-2 (SIAH2), on SIAH1 or on WD40-repeat/SOCS box
protein-1.
63 At last, a transcriptional repression of the human
p53 gene was shown when HIF-1a was overexpressed.
64
To conclude, these numerous studies showed that mild
hypoxia could decrease p53 protein level. This decrease
could contribute to protect the cells against apoptosis and
allow their adaptation to the hypoxic environment.
Effects of the combination of hypoxia with other
stresses on p53. When hypoxia is followed by a reoxy-
genation phase, p53 can be upregulated during this latter
phase and promote apoptosis, mitigating the conco-
mitant activation of the protective HIF-1 pathway. This has
been described, for example, in ischaemia-reperfusion injury
in the kidney.
65 Pires et al.
49 showed that, in RKO cells, after
reoxygenation, there was a signiﬁcant increase in p53-
dependent apoptosis. p53 target gene transcription is
induced during the reoxygenation phase, as it has been
observed for p53 apoptosis effector related to PMP-22 in
the outer medullary proximal tubular cells in post-reperfusion
ischaemic kidneys.
66 Hammond et al.
31 showed also that
reoxygenation induces phosphorylation of p53 Ser15 in a
ATM-dependent manner. However, if the duration of the
reoxygenation phase is long enough, p53 level returns to
normal level,
17 cancelling the effect of the hypoxia phase.
When hypoxia is combined with DNA damage, different cell
responses have been described. Some studies showed that
MDM2 Siah2 Siah1 WSB1
calpains MDMX CK2 NPM ROS
? HIPK2
p38
transcription
p53 gene translation
degradation
positive regulation
negative regulation
HYPOXIA / HIF-1
Ub
inactive
p53 protein
p53 protein
Figure 2 Schematic representation of the different pathways that have been proposed to explain the hypoxia-induced decrease in p53 gene transcription, p53 protein
stability and activity as well as the hypoxia-induced increase in p53 protein degradation. CK2, casein kinase 2; HIF-1a, hypoxia-inducible factor-1a; HIPK2, homeodomain-
interacting protein kinase 2; MDM2, murine double minute 2; NPM, nucleophosmin; ROS, reactive oxygen species; SIAH, seven in absentia homolog; Ub, ubiquitin; WSB-1,
WD40-repeat/SOCS box protein
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response or that a small additive effect is observed.
18,67
Others showed that hypoxia inhibits the increase in p53
protein level as well as cell death in response to etoposide,
68
5-ﬂuorouracil
69 or cisplatin.
70
In conclusion, according to the severity and duration of
hypoxia, as well as to the cell line, the effects of the oxygen
deﬁciency on p53 can be different. When p53 level is
increased, it seems to be dependent on HIF-1a and p53 has
mainly trans-repressional activity. Most of the time, the
hypoxia-induced increase in p53 protein level leads to cell
death.
Hypoxia Selects for Cells with Mutant p53
Intumours,hypoxiczonesoftencorrelatewithoverexpression
of mutant p53 protein. It was shown that the study of p53 and
HIF-1a protein level in tumours in vivo can be used to
discriminate different prognostic subgroups. Indeed, several
studies showed that the immunohistological detection of
a functionally inactive p53 and the presence of hypoxia have
no prognostic impact if analysed as single parameters, but
the combination of both parameters indicates an aggressive
phenotype with an adverse prognosis in various cancer
types.
71
It has also been shown that hypoxia contributes to the
selection of cells with decreased apoptotic potential and high
metastaticcapability.
57,72 This could be dueto the selection of
cells expressing mutant p53. Indeed, in 1996, Graeber et al.
73
showed that hypoxia induces p53-dependent apoptosis and
therefore counterselects cells with wild-type p53. A small
number of transformed cells lacking functional p53 then
overtake cells expressing wild-type p53 under hypoxic condi-
tions. This process therefore facilitates the clonal expansion
of cells with compromised p53 protein function.
The hypoxia-induced selection of mutant p53 has
adverse effect for patients because mutant p53 protein has
a dominant-negative effect on the wild-type protein, thus
preventing apoptosis. Some mutants might even present a
gain of function leading to oncogenic development.
2,74 Kamat
et al.
75 showed indeed that, in MCF-7 cells, mutant p53
facilitates pro-angiogenic and hyperproliferative phenotype
with decreased apoptosis in response to chronic hypoxia as
compared with wild-type p53. These data suggest that a
change in p53 status in tumour cells switches their phenotype
in response to chronic hypoxia into a more aggressive
phenotype.
Effects of p53 on HIF-1a Protein Level and HIF-1 Activity
Although hypoxia and HIF-1 are described to have various
effects on p53 protein level and activity, the reverse has also
been demonstrated.
p53 decreases HIF-1a protein level. In 2000, Ravi et al.
76
observed higher HIF-1a protein level in p53
 /  cells than in
p53
þ/þ cells. They showed that p53 promotes ubiquitination
and proteasomal degradation of HIF-1a. Others conﬁrmed
this observation by showing higher basal HIF-1a level in
response to hypoxia in p53-mutant cells than in p53-wild-type
cells.
75 Both studies suggest that the binding of MDM2 to p53
is needed for this effect. However, these observations are
contradictory to others. Choy et al.
77 showed indeed that
prolonged desferrioxamine incubation of rat cardiac myo-
blasts H9c2 induces p53 activation and HIF-1a proteasomal
degradation but this degradation occurred independently
of MDM2. Furthermore, it was shown that the interaction of
MDM2 with HIF-1a increases HIF-1 activity,
78,79 while others
did not observe any effect of MDM2 loss on HIF-1 target
genes expression.
38 Although a negative effect of p53 on
HIF-1a protein level has frequently been observed, it is
therefore difﬁcult to conclude about the involvement of
MDM2. It is possible that MDM2 implication in mediating
this effect could be cell-type dependent and may vary
according to the severity of the hypoxia. The involvement
of MIF (macrophage migration inhibitory factor) in this effect
has also been suggested. MIF, which is induced in a HIF-1-
dependent manner, increases HIF-1a protein level under
hypoxic conditions by binding p53 and sequestrating it from
HIF-1a.
80 Finally, it was also shown that the decrease in HIF-
1a protein level induced by p53 overexpression occurs via
a pVHL- and p300-independent mechanism
34 but that it can
be inhibited by AKT activation.
77
These observations were not only reported in vitro but
also in vivo. p53 KO mice displayed higher HIF-1a level than
WT mice following chronic hypoxia exposure.
81 Sustained
pressure overload, because of severe transverse aorta
constriction, induces p53 accumulation that decreases
HIF-1a level and thereby impairs cardiac angiogenesis and
systolic function.
82 In the kidney, p53 activation after
ischaemia-reperfusion injury mitigates the activation of the
protective HIF-1 pathway by decreasing HIF-1a protein
level.
65 Several immunohistological studies also suggest that
p53 modulates HIF-1a amount and activity: indeed, expres-
sion of HIF-1a protein is positively correlated with aberrant
p53 accumulation, which means accumulation of mutated
p53, as well as with low p53-dependent transcription.
83
Besides targeting HIF-1a, it was recently shown that p53
could also decrease HIF-1b protein level.
84,85 This effect is
mediated by the transcriptional upregulation of miR-107 that
targets HIF-1b 30UTR. This leads to a decrease in HIF-1
activity.
84
p53 has no effect on HIF-1a protein level. On the other
hand, several reports showed that hypoxia-induced p53 has
no effect on HIF-1a protein level. Indeed Achison and Hupp
69
found comparable HIF-1a protein level in HCT116 p53
þ/þ or
p53
 /  cells under mild hypoxia. Others also observed that
p53 has an effect on HIF-1a abundance only if artiﬁcially
overexpressed
34 or if concomitantly activated by DNA
damage.
48 This was conﬁrmed by Yang et al.
86 who
showed that induction of p53 alone is insufﬁcient to block
HIF-1a induced by hypoxia but that p53 activation by
the small molecule RITA (reactivation of p53 induction of
tumour cell apoptosis) inhibits HIF-1a and VEGF (vascular
endothelial growth factor) expression in vivo. This effect was
probably mediated by the activation of a DNA damage
response by RITA, inducing a p53-dependent increase in
phosphorylation of the alpha subunit of eukaryotic initiation
factor 2, which leads to the subsequent downregulation of
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86 It is therefore likely that the
induction of HIF-1a protein degradation by p53 occurs only in
cases of severe stress.
p53 inhibits HIF-1 activity. A number of studies also
showed that p53 can inhibit HIF-1 activity without affecting
HIF-1a protein level.
34 This effect seems to be independent
of p53 DNA-binding activity
60,87 but depends on a compe-
tition between p53 and HIF-1 for the binding of the transcrip-
tional co-activator p300.
34,87 In vivo also it was shown by
immunohistochemistry in early-stage invasive breast cancers
that the most unfavourable situation for HIF-1a to initiate
downstream gene expression would be the absence or low
expression of p300 and the presence of wild-type p53.
88
However, Liu et al.
89 did not ﬁnd that the HIF-1-mediated
gene expression in wild-type p53 cells was lower than in
cells with mutated p53 but that some forms of mutant p53,
when constitutively accumulated, can decrease the HIF-1-
dependent transcription of genes. Finally, others observed
that, although p53 null astrocytes harbour a markedly
increased HIF-1a-dependent target expression compared
with control cells, this altered expression was the result of
increased cell density in p53 null cultures and of the
accompanying acidosis but not of the loss of p53 protein by
itself.
38 These apparently opposite results could be explained
as follows: if p300 abundance is limited, a strong increase in
p53 protein level would decrease HIF-1 activity by
sequestering p300. However, if the basal p53 level is low,
no effect of its suppression would be observed on HIF-1
activity because the abundance of free p300 is sufﬁcient to
sustain HIF-1 activity.
In conclusion, p53 is frequently described to have negative
effects on HIF-1. In case of severe stress, p53 could induce
HIF-1a protein degradation although in milder conditions, p53
can inhibit HIF-1 activitywithout affecting HIF-1a protein level.
Direct and Indirect Interactions between p53 and HIF-1a
As previously described, hypoxia has been shown to
decrease or increase p53 protein level according to the
durationandseverityofhypoxiaand/orthecelltype,whilep53
is described to decrease HIF-1 activity and/or HIF-1a protein
level in case of severe stress. A part of these observations
have been explained by direct interaction between these two
proteins while other hypotheses imply the formation of larger
complexes containing both proteins. Several reports have
indeed shown that, in some conditions, HIF-1a and p53 co-
immunoprecipitate in cells incubated in vitro under hypoxia as
well as in vivo after ischaemia.
11,60,82
Direct interaction between HIF-1a and p53 has been
demonstrated. Although phosphorylated HIF-1a binds
HIF-1b, the dephosphorylated form of HIF-1a seems to be
the major form that binds to p53, both forms being induced by
hypoxia.
90 Using binding afﬁnity experiments, it was shown
that p53 DNA-binding domain interacts with two sequence
motifs of HIF-1a, leading to the hypothesis that each
sequence motif in HIF-1a binds to a different subunit of the
p53 tetramer.
91 These binding data support the hypothesis
that p53 provides a route for the degradation, in hypoxic cells,
of HIF-1a that is not hydroxylated at the two proline
residues.
91 Sanchez-Puig et al.
92 also showed that the
natively unfolded HIF-1a ODD (oxygen-dependent degrada-
tion domain) binds to full-length p53 to give a complex
containing one HIF-1a ODD and a p53 dimer. This binding
probably abolishes the ability of p53 to bind DNA and thus
hampers gene transactivation and p53-mediated apoptosis.
However, it is not sure whether this kind of interaction can
really occur in vivo.
93
Trimeric complexes containing p53, MDM2 and HIF-1a
have also been proposed with the hypothesis that it could
promote HIF-1a degradation.
76 This ternary complex could
possibly form with a direct interaction between p53 and
HIF-1a as described before.
90,92 However, according to Chen
et al.,
16 MDM2 is required to bridge the two proteins, thereby
facilitating HIF-1a degradation and the activation of p53-
mediated transcription. HIF-1a has indeed been shown to
interact directly with MDM2, even in the absence of p53.
78
LaRuschetal.
79conﬁrmedthedirectinteractionofHIF-1awith
MDM2 but their results do not support the trimeric model with
p53 because they could not co-immunoprecipitate the three
proteins together. They showed indeed that HIF-1a binds to
the p53-binding domain of MDM2, leading then to the
formation of two distinct complexes: MDM2-HIF-1a and
MDM2-p53. In these conditions, MDM2 does not promote
HIF-1a protein degradation but, on the contrary, increases its
abundance as well as HIF-1 activity in hypoxic cells.
78,79 A
trimeric complex containing MDM2, HIF-1a and p300 may be
involved in the induction of HIF-1 target genes
79 because the
binding of MDM2 to p300 has been evidenced.
94 Finally, a
trimeric complex with the stoichiometric binding of p53 to a
HIF-1/p300 complex has also been suggested.
87 The
existence of the trimeric complex p53/MDM2/HIF-1a is there-
fore still controversial.
Finally, an important role for JAB1 (jun activating binding
protein 1, also called CSN5) in regulating the HIF-1/p53
interactions has been proposed.
95 JAB1 and p53 bind
competitively to the same domain of HIF-1a resulting in either
stabilisation or degradation of HIF-1a respectively.
96 More-
over, p53 is stabilised by its binding to HIF-1a, whereas its
interaction with JAB1 induces p53 degradation.
97 This
suggests that the ratio between p53 and JAB1 determines
whether hypoxia-induced accumulation of HIF-1a results in
apoptosis through p53 stabilisation or adaptation through p53
degradation, with JAB1 being the factor promoting adapta-
tion.
95 The study of JAB1 expression and regulation at
different oxygen levels and in various cell types would be of
great interest. Indeed, it could help to reconcile the different,
and frequently opposite, models cited here about the
reciprocal effects between p53 and HIF-1a.
Interplay between the HIF-1a/pVHL Couple and the
p53/MDM2 Couple
The main proteins known to regulate HIF-1a and p53 levels
are their ubiquitin ligases: pVHL and MDM2, respectively. It is
thus interesting to understand how these four proteins
regulate each other (Figure 3). As previously described,
pVHL has a negative role on HIF-1a
98 and MDM2 on p53.
5,6
However HIF-1a has a positive role on pVHL
99 and p53 on
MDM2
100 because these regulators are target genes of the
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tightly interconnected and there obviously exists a functional
Yin-Yang relationship between MDM2-p53 and pVHL-HIF-1a
pairs.
101
As described previously, p53 has negative effects on HIF-
1a while HIF-1a seems to have mainly positive effects on p53.
MDM2 is also described to have mainly positive effects on
HIF-1a via a direct interaction between both proteins.
78,79
Furthermore, p53 has negative effects on pVHL by inducing
dramatic changes in its expression and intracellular localisa-
tion in the kidney after ischaemia-reperfusion injury.
65 On the
otherhand,pVHLhasapositiveeffectonp53.Indeed,Galban
et al.
24 showed that pVHL elevates p53 expression by
enhancing p53 translation while Roe et al.
102 showed that
pVHL directly associates with and stabilises p53 by suppres-
sing MDM2-mediated ubiquitination and p53 nuclear export.
After genotoxic stress, pVHL blocks MDM2-mediated degra-
dation of p53 by recruiting ATM and mediating ATM-
dependent Ser15 p53 phosphorylation. pVHL also increases
theinteractionbetweenp53andp300andthep53acetylation,
which ultimately leads to an increase in p53 transcriptional
activity and hence in p53-mediated cell cycle arrest and
apoptosis. Therefore, they suggest that pVHL serves as a
cofactor for strengthening the formation of ATM-p53-p300
complex when cells sense DNA damage.
102 These studies
suggest again a potential reciprocal regulatory effect for the
pVHL/p53 couple. Until now, nothing has been reported about
a hypothetical reciprocal effect of MDM2 and pVHL on each
other but Roe and Youn
101 suggest that pVHL could
negatively regulate the function of MDM2. The conclusion is
that each of these four proteins (HIF-1a, pVHL, p53 and
MDM2) can affect the three others leading to a very complex
network.
Contradictory or Synergistic Effects of p53 and HIF-1
in Regulating the Same Pathways
p53 and HIF-1a are proteins that have a lot of common points.
They both function as transcription factors and both proteins
are present in very low amounts in basal conditions because
of their degradation mediated by ubiquitin ligase, degradation
that is hampered during stresses. In addition, most pathways
regulated by p53 and by HIF-1 are the same. Both transcrip-
tion factors are indeed involved in regulating apoptosis,
survival, cell cycle, glycolysis, respiration and angiogenesis
among others. However, they sometimes act synergistically
and sometimes in a contradictory manner.
Apoptosis and survival. Several p53 target genes have a
pro-apoptotic function and p53 also induces apoptosis by
repressing the expression of pro-survival genes or even by
acting directly at the mitochondrial level.
103 Paradoxically, it
seems that in basal conditions, the low level of p53 induces
anti-apoptotic and anti-oxidant genes as well as genes
involved in DNA repair, therefore promoting cell survival.
104
p53 would induce apoptosis only when the cell is severely
damaged.
Similarly to p53, hypoxia also has pro- or anti-apoptotic
effects according to the intensity of the hypoxic stress.
105
Exposure to severe hypoxia leads to p53 accumulation and to
the induction of apoptosis.
7,105 Moreover, some HIF-1 target
genes code for pro-apoptotic proteins such as BNIP3 or
NIX.
106 However, hypoxia can also induce the expression
of pro-survival genes such as Mcl-1 or IAP-2 and inhibits
apoptosis.
68 It is currently unknown if the HIF-1 target genes
that are expressed under mild or severe hypoxia are the same
but we suggest that they could be different because HIF-1
possesses two transcriptional activation domains that are
activated at different pO2.
107
Cell cycle arrest. When a cell is slightly damaged, p53
induces cell cycle arrest in order for the cell to repair this
damage. The G1-arrest is mainly mediated via induction of
the cyclin-dependent kinase inhibitor p21 and the control of
the G2 checkpoint by p53 depends on induction of 14-3-3d.
These cycle arrest proteins also possess anti-apoptotic
activities.
104 The cessation of growth is also a classical
cellular response to hypoxia especially via the induction of
the cyclin-dependent kinase inhibitors p21 and p27 as well
as via the hypophosphorylation of retinoblastoma protein.
27
p53 and hypoxia therefore acts synergistically to induce
cell cycle arrest via p21 upregulation for example. However,
in some conditions, hypoxia also induces cell proliferation
via the induction of various growth factors such as insulin-
like growth factor-2 and platelet-derived growth factor.
1
Such a pro-proliferative effect has not been described
for p53.
Glycolysis, respiration and ROS production. During
tumourigenesis, one of the main functions of hypoxia is to
induce a metabolic switch of glucose metabolism from
respiration to glycolysis. It is now more and more accepted
that the loss of p53 function also contributes to this switch.
108
Under hypoxia, HIF-1 has been shown to regulate the
expression of nearly all the enzymes of the glycolytic
pathway, as well as to induce the expression of glucose
transporters.
1 Besides activating glycolysis, hypoxia also
actively inhibits mitochondrial respiration by inhibiting the
conversion of pyruvate into acetyl-coenzyme 1 and by
Figure 3 Schematicrepresentationofthereciprocal modulationofHIF-1a,p53,
pVHL and MDM2
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chain.
109
p53 also modulates the balance between the utilisation of
the respiratory and glycolytic pathways but in an opposite way
to hypoxia, by promoting oxidative phosphorylation and
dampening glycolysis.
110 p53 promotes mitochondrial
respiration especially by upregulating synthesis of cytochrome
c oxidase 2 and the loss of its expression in p53-mutated cells
recapitulates the metabolic switch.
111 The observation that
protein levels of the cytochrome c oxidase II subunit as well as
mitochondrial cytochrome c oxidase activity are decreased in
p53
 /  cells suggests also the involvement of p53 in the
positive regulation of mitochondrial respiration.
112 Recently,
glutaminase 2, a protein known to enhance mitochondrial
respiration, has also been identiﬁed as a p53 target gene.
113
Furthermore, glycolysis was shown to be inhibited by p53 via
the upregulation of TIGAR (TP53-induced glycolysis and
apoptosis regulator) that lowers fructose-2,6-bisphosphate
level.
114 The expression of glucose transporters is also
decreased by p53.
115
These metabolic pathways are associated with ROS
production. The relationship between hypoxia and the
production of ROS is controversial. Depending on the studies,
hypoxia was described to increase or to decrease ROS
production.
116 p53 has also opposite effects. It seems that,
under severe stress, p53 increases ROS production and cell
death whereas in the absence of stress, low levels of p53
induce a decrease in intracellular ROS level.
110,117 Basal p53
level has indeed an antioxidant function.
104 For example,
p53-induced upregulation of glutathione peroxidase, TIGAR,
glutaminase 2 and sestrins contributes to decrease intra-
cellularROSlevels.
104,113,114p53andhypoxiacouldtherefore
act together or in an opposite way to positively or negatively
regulate ROS production.
Angiogenesis. Hypoxia is a well-known inducer of angio-
genesis and vascularisation of hypoxic zones is necessary
for further tumour development. HIF-1a stabilisation leads to
the transcription of target genes involved in growth of blood
vessels such as VEGF, inducible nitric oxide synthase,
ﬁbroblast growth factor and matrix metalloproteinases.
1 The
notion that p53 has a role in limiting tumour vascularisation
has come from a number of clinical studies showing correla-
tions between mutated p53, greater VEGF levels and
microvessel density.
118 At least three mechanisms are
used by p53 to inhibit angiogenesis. First, it increases the
production of antiangiogenic factors
118 among them, is
thrombospondin-1. Second, p53 directly inhibits the HIF-1
pathway. Finally, p53 transcriptionally represses genes
encoding proangiogenic factors, including VEGF and basic
ﬁbroblast growth factor.
119,120
Conclusion
p53 and HIF-1 are two transcription factors that have been
extensively studied during the last two decades since they
bothhavemajorrolesinnumerouspathwaysofcellslivingina
hypoxic environment. One of the main common features of
these proteins is that both factors have the possibility to
promotecellsurvivalandadaptationtoamildstressaswellas
to induce cell death when the cell is confronted to a more
severe stress. Under hypoxia and depending on the condi-
tions, itseems thatthey canboth workin the samedirection or
show opposing activities. According to all what has been
reported until now, we hypothesise the following model
(Figure 4). Under basal normoxic conditions, the abundance
ofp53andHIF-1aisvery low.Whentheoxygenconcentration
decreases, HIF-1a is stabilised and HIF-1 induces the
expression of its target genes that are involved in survival.
NORMOXIA
MILD
HYPOXIA 
ANOXIA
LOW HIF-1α
(VERY) LOW p53 HIGH HIF-1α
SURVIVAL
APOPTOSIS
HIGH p53
LOW p53
HIGH HIF-1α
LOW HIF-1α
SURVIVAL
APOPTOSIS
HIF-1α stabilization
p53 levels can be decreased 
p53-dependent HIF-1α degradation 
decreased HIF-1 activity due to competition with p53 for
coactivators
Decreased pO2
Increased duration
Transactivation activity not frequently described
Induction of protective, anti-apoptotic genes
Induction of pro-apoptotic genes
p53 is stabilized
HIGH p53
SEVERE
HYPOXIA
Figure 4 Model for the regulation of p53 and HIF-1a protein level as well as of p53 and HIF-1 activity depending on the severity and the duration of hypoxia
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cells from apoptosis. If the oxygen concentration decreases
more and/or if hypoxia lasts too long, HIF-1 induces p53
stabilisation, leading to apoptosis. A competition between
these two proteins then occurs for co-activators resulting in a
decrease in HIF-1-transactivating activity. Finally, under
strongly anoxic conditions, p53 eventually leads to HIF-1a
degradation. All the factors responsible for the transition
between the pro-survival state and the pro-death state are not
completely understood yet but it certainly depends on the
duration and severity of the hypoxia. Moreover, the exact
conditions responsible for the transition from one state to the
otherseemtobedifferentaccordingtothecelltype.Thestudy
of the expression of proteins such as JAB1 or CSB in different
conditions will help to better understand how p53 and
HIF-1a expression and activity are modulated. Other additive
stresses such as reoxygenation, acidosis or DNA damage
also modulate this balance. Among the questions that have
not been assessed yet, it is interesting to know if the HIF-1
target genes expressed under mild hypoxia are the same that
the ones expressed under severe hypoxia. It is indeed not
clear whether, after p53 hypoxic stabilisation, HIF-1 and p53
are both working for inducing apoptosis or whether both
factors promote opposite cell behaviour. The regulation of
survival and death mediated by p53 and HIF-1 under hypoxia
is therefore extremely complex. It is, however, very important
to progress in the comprehension of the interplay between
these two transcription factors in order to improve the
understanding of various diseases and to design new
therapeutic approaches.
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